Wells Fargo & Company has lowered its price target for biopharmaceutical company Incyte (NASDAQ:INCY) from $107 to $101, maintaining an “equal weight” rating. This decision follows Incyte’s Q4 earnings, which showed a revenue beat but an EPS miss, along with a softer 2026 revenue outlook and concerns regarding its drug Opzelura and Jakafi’s patent and generic exposure. Despite institutional investors holding a large stake, insiders have recently sold a significant number of shares.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00
Wells Fargo & Company has lowered its price target for biopharmaceutical company Incyte (NASDAQ:INCY) from $107 to $101, maintaining an “equal weight” rating. This decision follows Incyte’s Q4 earnings, which showed a revenue beat but an EPS miss, along with a softer 2026 revenue outlook and concerns regarding its drug Opzelura and Jakafi’s patent and generic exposure. Despite institutional investors holding a large stake, insiders have recently sold a significant number of shares.